Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly EBIT Margin of 10173.74% in Q3 2025, up 43.78% quarter-over-quarter from 18096.89% in Q2 2025, and down 879713.0% on a YoY basis from N/an in Q3 2024.
Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' EBIT Margin history runs 4 years deep, the most recent figure standing at 10173.74% for Q3 2025.
- In Q3 2025, EBIT Margin fell 879713.0% year-over-year to 10173.74%; the TTM figure through Sep 2025 stood at 4504.27% (down 295031.0% YoY), while the FY2024 annual figure was 1633.74%, up 7093.0% from the prior year.
- EBIT Margin was 10173.74% for Q3 2025 at Dianthus Therapeutics, up from 18096.89% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 703.67% in Q3 2022 to a low of 18096.89% in Q2 2025.
- Historically, EBIT Margin has averaged 3635.65% across 4 years, with a median of 1751.0% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin jumped 63438 bps in 2024, then tumbled 1690505 bps in 2025.
- A 4-year view of EBIT Margin shows it stood at 923.4% in 2022, then slumped by 229 bps to 3041.31% in 2023, then increased by 21 bps to 2406.94% in 2024, then tumbled by 323 bps to 10173.74% in 2025.
- The last three EBIT Margin figures came in at 10173.74% (Q3 2025), 18096.89% (Q2 2025), and 2764.75% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10,173.74% |
| Jun 30, 2025 | -18,096.89% |
| Mar 31, 2025 | -2,764.75% |
| Dec 31, 2024 | -2,406.94% |
| Sep 30, 2024 | -1,376.61% |
| Jun 30, 2024 | -1,191.84% |
| Mar 31, 2024 | -2,041.65% |
| Dec 31, 2023 | -3,041.31% |
| Sep 30, 2023 | -1,751.00% |
| Jun 30, 2023 | -1,177.60% |
| Mar 31, 2023 | -1,614.08% |
| Dec 31, 2022 | -923.40% |
| Sep 30, 2022 | -703.67% |